■ Miniject, Istar Medical’s supraciliary MIGS device, has now initiated a trial in 13 sites across the United States with positive feedback on initial implantations from world-leading glaucoma surgeons, the company noted in a news release.
In the more than 150 patients so far enrolled in completed and ongoing trials conducted in Europe, the Americas, and Asia, Miniject has demonstrated meaningful and enduring IOP reduction with a favorable safety profile, according to the company. The STAR-V trial is assessing the safety and efficacy of Miniject in more than 350 patients with POAG across the United States, Canada, and Europe.
“There is significant untapped potential in targeting the supraciliary space when leveraging MIGS to treat glaucoma, and Miniject enables this to be captured,” said Steven D. Vold, MD, of Vold Vision in Fayetteville, Arkansas, in a news release. “The supraciliary space has previously been demonstrated to be one of the most efficacious targets, and I am excited at the prospect of having a new MIGS approach with such strong potential to offer my patients.”